Episode 387: ASCO GU 2025 - Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: Updated Efficacy and Safety Results

Xinan Sheng, MD, Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital & Institute in Beijing, China, joins the podcast to discuss the update of this trial and impressive pCR rates.